Eli Lilly and Company (NYSE:LLY) Stake Raised by Wulff Hansen & CO.

Wulff Hansen & CO. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 90,438.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 937,068 shares of the company’s stock after acquiring an additional 936,033 shares during the quarter. Eli Lilly and Company comprises approximately 4.5% of Wulff Hansen & CO.’s investment portfolio, making the stock its 5th largest holding. Wulff Hansen & CO.’s holdings in Eli Lilly and Company were worth $848,403,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Citizens Financial Group Inc. RI grew its position in shares of Eli Lilly and Company by 34.1% during the second quarter. Citizens Financial Group Inc. RI now owns 53,087 shares of the company’s stock worth $48,064,000 after buying an additional 13,488 shares in the last quarter. Total Clarity Wealth Management Inc. increased its position in shares of Eli Lilly and Company by 2.6% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 1,030 shares of the company’s stock valued at $932,000 after purchasing an additional 26 shares during the last quarter. One Capital Management LLC increased its position in shares of Eli Lilly and Company by 17.1% in the 2nd quarter. One Capital Management LLC now owns 1,953 shares of the company’s stock valued at $1,768,000 after purchasing an additional 285 shares during the last quarter. Menard Financial Group LLC raised its holdings in shares of Eli Lilly and Company by 3.9% in the 2nd quarter. Menard Financial Group LLC now owns 744 shares of the company’s stock valued at $674,000 after purchasing an additional 28 shares in the last quarter. Finally, American Planning Services Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $2,347,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Barclays raised their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday. Finally, BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 451,900 shares of company stock worth $418,732,178. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.0 %

NYSE:LLY opened at $924.05 on Tuesday. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock’s 50 day simple moving average is $897.24 and its 200-day simple moving average is $835.09. The firm has a market cap of $878.22 billion, a P/E ratio of 136.09, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Equities analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.